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Abstract 
Purpose 
To report the long-term efficacy of endoscopic cyclophotocoagulation (ECP) in pediatric 
glaucoma following cataract surgery (GFCS).  
Methods 
ECP was performed on 35 eyes of 25 patients <16 years of age with GFCS. Patients were 
followed for a minimum of 2 years. Treatment failure was defined as consecutive postoperative 
intraocular pressure (IOP) of >24 mm Hg, alternative glaucoma procedure following ECP, or 
occurrence of visually significant complications. Analysis was performed to estimate risk factors 
for failure. 
Results 
A total of 27 aphakic and 8 pseudophakic eyes were included. Pretreatment IOP averaged 33.9 ± 
7.9 mm Hg. Final IOP after a mean follow-up period of 7.2 years was 18.9 ± 8.8 mm Hg (P < 
0.001). The success rate was 54% (19/35 eyes). The failure rate was not increased in 
pseudophakic patients relative to aphakic patients. Patients with single ECP demonstrated 
preserved visual acuity from baseline to final follow-up. 
Conclusions 
In this patient cohort, with average follow-up period of 7.2 years, ECP was useful in the 
treatment of pediatric GFCS.  
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Development of glaucoma following cataract surgery (GFCS) is common. According to the 
Infant Aphakia Treatment Study (IATS), the risk of developing glaucoma at 4.8 years after 
surgery is 17%; of being a glaucoma suspect, 31%.1 These patients are often inadequately 
responsive to medical management. Surgical options include trabeculectomy, seton implantation, 
and cyclodestructive procedures.  
Endoscopic cyclophotocoagulation (ECP) is a ciliary destructive procedure used in the 
management of a variety of glaucoma cases. Its utility has been demonstrated in studies of 
difficult secondary glaucomas in which the etiology of increased intraocular pressure (IOP) was 
varied.2,3 ECP has been shown to be effective as a primary intervention for cases of GFCS in 
young children, with minimum follow-up of 1 year and an average follow-up of 3.7 years.2 The 
current study reviewed the records of both aphakic and pseudophakic patients treated with ECP 
to better understand the benefit to each, expanding previous studies by providing longer follow-
up, longitudinal analysis of postoperative IOP, and reporting visual acuity as a functional 
outcome of the procedure. This study also investigated whether pseudophakia is a risk factor for 
treatment failure. 
Subjects and Methods 
The Indiana University Institutional Review Board approved this study, which was performed in 
accordance with the US Health Insurance Portability and Accountability Act of 1996. Suitable 
patients were identified by procedure codes, and patients’ medical records were reviewed 
retrospectively. Children <16 years of age with GFCS treated with ECP from 1994 to 2014 at 
Riley Hospital for Children at IU Health in Indianapolis, Indiana, and followed for a minimum of 
2 years or until a treatment failure had been declared were included. Patients with congenital 
glaucoma, anterior segment dysgenesis, or other secondary glaucomas were excluded. 
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Treatment failure was defined as the occurrence of any of the following during 
postoperative follow-up: (1) IOP >24 mm Hg on two consecutive visits despite glaucoma 
medications; (2) any other glaucoma procedure subsequent to ECP; or (3) sight-threatening 
complications, such as hypotony or retinal detachment. Treatment was considered successful if 
none of these failure criteria were met from time of surgery to final follow-up. 
The diagnosis of GFCS was based on unacceptable IOP combined with evidence of optic 
nerve damage. Medical therapy was instituted in most patients prior to the first ECP treatment. In 
all patients, ECP was the first glaucoma surgical intervention. Any eye that had a suboptimal 
IOP and received further ECP was not deemed a treatment failure unless IOP at final follow-up 
exceeded that required for the definition of success. Alternative glaucoma interventions such as 
tube-shunt placement were performed by the primary surgeons if the IOP rebounded despite 
adequate degrees of treatment during ECP. 
 Treatment for all patients was administered with the Microprobe (Endo Optiks Inc, Little 
Silver, NJ). A schematic illustration of this procedure has been previously published.2 Specific 
technique as well as preoperative and postoperative care was held consistent to the methods 
described in detail by Carter and Plager.2 Treatments ranged from 120° to 270°. With rare 
exception, follow-up examinations took place at postoperative day 1, week 1, and months 1, 3, 
and 6. Subsequent examination intervals were based on the patient’s clinical course. Visual 
acuity was collected based on age-appropriate tests, including Allen symbols, HOTV chart, and 
Snellen chart at 20 feet. Data collected included current medications, visual acuity, and IOP. 
Results 
A total of 35 eyes of 25 patients were included: 15 patients had bilateral cataracts and bilateral 
glaucoma; 6 patients had bilateral cataracts and unilateral glaucoma; and 4 patients had unilateral 
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cataract and unilateral glaucoma. Patient characteristics and baseline data, including phakic 
status, age at time of procedure, IOP, and follow-up, are summarized in Table 1.  
At the final follow-up, median IOP was decreased by 47% in all patients in relation to the 
preoperative baseline. On average, the diagnosis of GFCS was made 3.3 years after lensectomy, 
and ECP was performed 2 years after diagnosis of GFCS. Of the 35 eyes included in this study, 
80% had single ECP; in this subgroup, 14% required further alternative surgery. Of the 35 eyes, 
20% required multiple ECP; 86% in this subgroup required further alternative surgery. 
Of the 35 eyes treated with ECP, 19 (54%) were considered treatment successes. 
Treatment was successful in 13 of 27 aphakic eyes (48%) and 6 of 8 pseudophakic eyes (75%). 
ECP was successful in 18 of 28 eyes (64%) that received one treatment and 1 of 7 eyes (14%) 
that received multiple treatments. The average degree of treatment for first ECP was 230°, 
whereas the average degrees of treatment for repeat ECP was 151°. Four patients had bilateral 
success, and 4 patients had bilateral failure. One patient had success in one eye and failure in the 
other eye. 
 Failed eyes demonstrated a higher baseline IOP. All eyes demonstrated a significant 
decrease in IOP in the first postoperative week. At 6 months postoperatively, the mean IOP in 
successfully treated eyes was 18.6 ± 4.0 mm Hg (range, 10–24 mm Hg); in failed eyes, 28.6 ± 
13.3 mm Hg (range, 12–53 mm Hg; P = 0.03).  
  Kaplan-Meier survival curves with 95% confidence intervals are shown for the 
single ECP group in Figure 1A and the multiple ECP group in Figure 1B. For the single ECP 
group, failure time was defined as time from baseline prior to first ECP procedure to the first 
treatment failure. For the multiple ECP group, failure time was defined as time from baseline to 
the second treatment failure. For the single ECP group, the failure probability was 0.21 (95% CI, 
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0.05-0.35) at 6 months, 0.32 (95% CI, 0.12-0.47) at 12 months, and 0.35 (95% CI, 0.15-0.51) at 
24 months. For the multiple ECP group, the second treatment failure probability was 0.57 (95% 
CI, 0.01-0.82) at 12 months, 0.72 (95% CI, 0.08-0.91) at 24 months, and 0.86 (95% CI, 0.13-
0.97) at 36 months. Single ECP eyes demonstrated a decrease in survival until 2 years, when 
there was no further decrease. All analyzed risk factors for ECP failure related to lensectomy, 
glaucoma diagnosis, and ECP are provided in Table 2. 
Of the 35 total eyes, 3 (9%) had visual acuity of hand motions or less at final follow-up. 
Of the 32 remaining eyes, in those which received single ECP, logMAR visual acuity 
demonstrated improvement from baseline at 0.87 ± 0.35 (range 0.30-1.60) to 0.63 ± 0.42 (range, 
0.00-1.48) at final follow-up (P < 0.01). Eyes that received multiple ECP treatments did not 
demonstrate significant change in visual acuity from baseline. 
The 3 eyes with visual acuity of hand motions or less experienced complications 
following surgical procedures other than ECP. One eye received pars plana vitrectomy and 
capsulotomy at 5 months after ECP and immediately developed endophthalmitis, which 
progressed to phthisis. One eye had G-probe performed 4 months after ECP and thereafter 
progressed to phthisis. One eye had 3 ECP procedures performed followed by a trabeculotomy 
then progressed to phthisis. There were no vision-threatening complications immediately 
following the ECP procedures. 
Discussion 
This study demonstrates that ECP in children with GFCS can be useful over an average follow-
up period of 7.2 years. Failed eyes demonstrated an elevated IOP at 6 months after ECP; thus an 
elevated IOP at this time may be a good predictor of whether a patient is likely to fail ECP. 
Almost all treatment failures occurred in the first 2 years, with sustained success thereafter in 
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eyes that underwent single ECP. 
The length of follow-up in this study has allowed us to better evaluate the visual acuities 
of these children, because many of the procedures were performed at an early age. An 
improvement in visual acuity from baseline was demonstrated in single ECP eyes from an 
approximate Snellen equivalent of 20/160 at baseline to 20/80 at the final follow-up. This data 
demonstrates prevention of vision loss rather than a causal relationship between the procedure 
and improvement in vision. The measured improvement in visual acuity may have been due to 
the child’s increasing maturity rather than a real improvement in acuity. 
The results in this study are comparable to those of the previous study in this patient 
population, which had a minimum follow-up of 1 year and an average follow-up of 3.7 years, 
with a success rate of 53%.2 The previous study found greater success in multiple ECP eyes, 
likely due to undertreatment of many eyes, with 180° rather than 270° followed by therapeutic 
treatment with repeat ECP. 
In the current study failed eyes had higher IOP at GFCS diagnosis and higher baseline 
number of glaucoma medications prior to ECP. This could represent eyes with poorer outflow. 
There was no increased risk of failure in pseudophakic eyes compared to aphakic eyes. No 
retinal detachments occurred in this study; however, there were 3 cases of phthisis, which 
developed after procedures other than ECP. 
GFCS is significantly more likely to develop in eyes with a corneal diameter of <10 mm 
compared with corneal diameter >10 mm and in all eyes with any degree of microcornea.4-6 The 
current study is consistent with these findings as the average corneal diameter at the time of 
cataract extraction was 9.5 ± 1.4 mm (range, 5.4–11.8 mm). Early age at cataract extraction is 
also a risk factor, with children <1 year of age carrying the greatest risk of developing 
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glaucoma.7 
Studies have demonstrated varying results related to laterality of disease.8,9 No cases of 
bilateral glaucoma in the setting of unilateral aphakia were identified in this study. Six eyes did 
have unilateral GFCS in the setting of bilateral aphakia; however, GFCS could develop in 
aphakic eyes after the period of follow-up in this study. 
This study has several limitations. A failure cutoff of 24 mm Hg was selected because 
IOPs were often elevated in the 21–24 mm Hg range following surgery, and there is inconclusive 
data associating initial mild elevation in IOP with optic nerve damage. Differences in IOP 
between successful and failed eyes may be small enough to not be clinically relevant. The 
sample size is small, and P < 0.05 is an insufficient cutoff for statistical significance because of 
investigation of multiple risk factors. Both eyes of bilateral cases were included because of the 
small sample size, which might skew results. Finally, no visual field or optical coherence 
tomography tests were analyzed in this study. 
Over an average follow-up period of 7.2 years, ECP is a viable treatment in the setting of 
GFCS with a moderate success rate and a low complication rate. Procedure failure rate was not 
increased in pseudophakic eyes, suggesting that the presence of an IOL may not affect the 
surgical outcome. Survival analysis demonstrates retreatment failed. This contrasts previous 
findings in which eyes received less degrees of treatment during the initial procedure.  
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Legends 
FIG 1. A, Survival analysis demonstrating time to first treatment failure in single endoscopic 
cyclophotocoagulation (ECP) group. B, Survival analysis demonstrating time to repeat treatment 
failure in multiple ECP group. 
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Table 1. Patient demographics and outcomes 
 
Patient demographics (N = 25) No. (%) 
Eyes (N = 35)  
Male 17 (49) 
Female 18 (51) 
Phakic status  
Aphakic 27 (77) 
Pseudophakic 8 (23) 
Treated bilaterally 10 (42) 
Treatment parameters Mean ± SD (range) 
Age, years  
Lensectomy 0.7 ± 1.7 (0.1-6.4) 
GFCS diagnosis 4.0 ± 2.5 (0.3-8.0) 
First ECP treatment 6.0 ± 3.8 (0.4-12.3)
Corneal diameter at lensectomy, mma 9.5 ± 1.4 (5.4-11.8)
IOP, mm Hg  
Baseline pre-ECP 34.1 ± 8.3 (20-50) 
Final 18.9 ± 8.8 (8-57) 
Follow-up time, years 7.2 ± 3.6 (2.2-17.1)
ECP, endoscopic cyclophotocoagulation; GFCS, glaucoma following. 
cataract surgery; IOP, intraocular pressure; SD, standard deviation. 
aRecorded in 18 of 35 eyes. 
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Table 2. Risk factors for failure 
 
 
Success Failure P 
value Mean ± SD (range) Mean ± SD (range) 
Lensectomy      
Age, years 0.8 ± 1.8 (0.1-6.4) 0.5 ± 1.5 (0.0-6.2) 0.65 
Time to first post-op IOP, years 1.1 ± 1.2 (0.1-4.5) 1.8 ± 2.1 (0.0-5.9) 0.24 
First measured post-op IOP, mm Hg 17 ± 7.8 (5-32) 25.1 ± 8.8 (14-42) 0.01 
Glaucoma diagnosis      
Time between lensectomy and glaucoma 
diagnosis, years 
3.8 ± 2.3 (0.2-7.9) 2.8 ± 2.5 (0.2-6.5) 0.23 
IOP at glaucoma diagnosis, mm Hg 28.6 ± 7.7 (21-48) 32 ± 6.4 (22-42) 0.16 
ECP      
Number of ECP treatments 1.1 ± 0.2 (1-2) 1.5 ± 0.7 (1-3) 0.03 
Degrees of treatment of 1st ECP 224 ± 47 (120-270) 238 ± 36 (180-270) 0.35 
Patient age at time of first ECP, years 7.1 ± 3.8 (0.4-12.3) 4.7 ± 3.5 (0.4-9.8) 0.06 
Time between lensectomy and ECP, years 6.3 ± 3.8 (0.2-12.1) 4.2 ± 3.6 (0.3-9.8) 0.09 
Time between 1st IOP after lensectomy and ECP, 
years 
5.2 ± 3.7 (0.0-11.4) 2.3 ± 2.5 (0.0-8.3) 0.01 
Time between glaucoma diagnosis and ECP, 
years 
3.3 ± 3.2 (0.1-9.6) 1.9 ± 2.0 (0.1-6.2) 0.11 
Baseline IOP at time of 1st ECP, mm Hg 32.1 ± 7.4 (20-48) 36.5 ± 8.8 (24-50) 0.12 
No. glaucoma medications    
Before ECP 1.8 ± 1.3 (0-3) 1.7 ± 1.0 (0-3) 0.95 
After ECP 0.8 ± 1.3 (0-3) 1.8 ± 1.2 (0-3) 0.03 
ECP, endoscopic cyclophotocoagulation; IOP, intraocular pressure; SD, standard deviation. 
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